(:NBRV)

Jul 10, 2023 04:01 pm ET
Arbutus Appoints Two New Executives
Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or the “Company”), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel therapeutics that target specific viral diseases, today announced the...
Jan 06, 2023 07:01 am ET
Nabriva Therapeutics Provides Corporate Update
Nabriva Therapeutics plc (NASDAQ: NBRV) today announced that, after an assessment of strategic options, its Board of Directors approved a plan to preserve cash in order to adequately fund an orderly wind down of the Company’s operations. As...
Nov 28, 2022 07:01 am ET
Nabriva Therapeutics Announces Positive Topline Results from Phase 1 Trial of XENLETA® (lefamulin) in Adult Patients with Cystic Fibrosis
Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, announced positive topline results from their Phase 1 clinical...
Nov 10, 2022 04:01 pm ET
Nabriva Therapeutics Pivoting Strategic Focus Reports Third Quarter Financial Results and Provides Corporate Update
Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced it has pivoted its strategic focus towards...
Nov 07, 2022 07:01 am ET
Nabriva Therapeutics to Report Third Quarter 2022 Financial Results and Recent Corporate Highlights on November 10, 2022
Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced that it will report its third quarter financial...
Sep 15, 2022 08:30 am ET
Thinking about buying stock in Nabriva Therapeutics, Sonnet BioTherapeutics, Fast Radius, Volcon, or Velo3D?
NEW YORK, Sept. 15, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for NBRV, SONN, FSRD, VLCN, and VLD.
Sep 15, 2022 07:01 am ET
Nabriva Therapeutics Announces Date of 1-for-25 Reverse Stock Split
Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced that it will effect a 1-for-25 reverse stock...
Sep 06, 2022 07:01 am ET
Nabriva Therapeutics to Participate in the H.C. Wainwright 24th Annual Global Investment Conference
Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced that Ted Schroeder, Chief Executive Officer at...
Aug 11, 2022 07:01 am ET
Nabriva Therapeutics Completes Patient Enrollment in Phase 1 Trial of XENLETA® (lefamulin) in Adult Patients with Cystic Fibrosis
Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, announced the completion of patient enrollment in its Phase 1...
Aug 03, 2022 04:01 pm ET
Nabriva Therapeutics Reports Second Quarter 2022 Financial Results and Provides a Corporate Update
Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced its financial results for the three months ended...
Jul 20, 2022 04:05 pm ET
Nabriva Therapeutics to Report Second Quarter 2022 Financial Results and Recent Corporate Highlights on August 3, 2022
Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced that it will report its second quarter financial...
Jul 18, 2022 07:01 am ET
Nabriva Therapeutics Expands XENLETA® (lefamulin) Presence with Exclusive Agreement with Er-Kim Pharmaceuticals
Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced that it has entered into an exclusive...
May 13, 2022 07:01 am ET
Nabriva Therapeutics to Present at the H.C. Wainwright Global Investment Conference
Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced that Ted Schroeder, Chief Executive Officer at...
May 05, 2022 04:01 pm ET
Nabriva Therapeutics Reports First Quarter 2022 Financial Results and Provides a Corporate Update
Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced its financial results for the three months ended...
May 05, 2022 07:01 am ET
Nabriva Extends Exclusive Agreement to Promote and Distribute SIVEXTRO® (tedizolid phosphate) in the U.S. Through the End of 2026
Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced that it agreed to an extension of its exclusive...
May 02, 2022 04:05 pm ET
Nabriva Therapeutics to Report First Quarter 2022 Financial Results and Recent Corporate Highlights on May 5, 2022
Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced that it will report its first quarter financial...
Apr 11, 2022 04:05 pm ET
Nabriva Therapeutics Announces First Patient Enrolled in Phase 1 Trial of XENLETA® (lefamulin) in Adult Patients with Cystic Fibrosis
Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, announced that the first patient was enrolled in a Phase 1...
Mar 29, 2022 04:01 pm ET
Nabriva Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides a Corporate Update
Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced its financial results for the three months and...
Mar 15, 2022 07:01 am ET
Nabriva Therapeutics to Report 2021 Financial Results and Recent Corporate Highlights on March 29, 2022
Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced that it will report its fourth quarter and full...
Mar 01, 2022 07:01 am ET
Nabriva Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced that it has granted a non-statutory stock option...
Jan 18, 2022 04:01 pm ET
Nabriva Therapeutics Adjourns Extraordinary General Meeting of Shareholders on January 18, 2022
Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced that it adjourned, without conducting any...
Jan 14, 2022 04:01 pm ET
Nabriva Therapeutics Adjourns Extraordinary General Meeting of Shareholders
Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced that it adjourned, without conducting any...
Jan 10, 2022 07:00 am ET
Nabriva Therapeutics Provides Business Update and Announces Preliminary Financial Results for the Fourth Quarter of 2021
Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, announced a business update today and preliminary, unaudited...
Dec 22, 2021 09:20 am ET
Nabriva Therapeutics to Adjourn Extraordinary General Meeting of Shareholders on December 22, 2021
Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced that it intends to adjourn, without conducting...
Dec 21, 2021 04:05 pm ET
Nabriva Therapeutics to Present at the H.C. Wainwright BioConnect Virtual Conference
Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced that Ted Schroeder, Chief Executive Officer at...
Nov 29, 2021 09:00 am ET
Lefamulin NDA Filed in Mainland China for Treatment of Community Acquired Pneumonia
Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, announced today that its partner, Sumitomo Pharmaceuticals’...
Nov 11, 2021 07:01 am ET
Nabriva Announces Availability of XENLETA® (lefamulin) in a 10-Count Oral Pack
Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced the oral formulation of XENLETA® (lefamulin) is...
Nov 09, 2021 04:01 pm ET
Nabriva Therapeutics Reports Third Quarter 2021 Financial Results and Provides a Corporate Update
Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced its financial results for the three months ended...
Nov 05, 2021 07:01 am ET
Nabriva Therapeutics to Present at the Jefferies London Healthcare Conference
Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced that Ted Schroeder, Chief Executive Officer at...
Nov 01, 2021 07:01 am ET
Nabriva Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced that it has granted a non-statutory stock option...
Oct 26, 2021 07:01 am ET
Nabriva Therapeutics to Report Third Quarter 2021 Financial Results and Recent Corporate Highlights on November 9, 2021
Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced that it will report its third quarter financial...
Oct 15, 2021 04:05 pm ET
Nabriva Therapeutics to Present Data at CHEST Annual Meeting 2021
Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today, announced data presentation at CHEST 2021, the annual...
Oct 04, 2021 04:05 pm ET
Nabriva Publishes Data Demonstrating the Potent Anti-Inflammatory Properties of XENLETA® (lefamulin)
Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today published the first data to demonstrate the...
Oct 01, 2021 04:05 pm ET
Nabriva Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced that it has granted a non-statutory stock option...
Oct 01, 2021 07:01 am ET
Nabriva Therapeutics Appoints Dr. Christine Guico-Pabia, M.D., as Chief Medical Officer
Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, announced the appointment of Dr. Christine Guico-Pabia, M.D.,...
Sep 30, 2021 08:00 am ET
Antimicrobials Working Group Highlights Member Company Participation at IDWeek 2021
WASHINGTON, Sept. 30, 2021 /PRNewswire/ -- The Antimicrobials Working Group (AWG), a coalition of companies with the mission to combat drug resistant infections and spur life-saving innovations, today announced that 10 of its member companies will present data from their clinical and research programs at IDWeek 2021 taking place virtually from September 29-October 3, 2021. AWG members are presenting a total of 23 poster presentations and 3 oral abstract presentations.
Sep 24, 2021 07:01 am ET
Nabriva Therapeutics to Present Data at IDWeek 2021
Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced data presentation at the Infectious Disease...
Sep 09, 2021 07:01 am ET
Nabriva and Vizient Enter into Agreement to Make XENLETA® (lefamulin) Available to Vizient’s Pharmacy Network Program
Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, announced that it has entered into an agreement with Vizient to...
Sep 08, 2021 09:31 am ET
Thinking about buying stock in Nabriva Therapeutics, WiMi Hologram Cloud, Xos Inc, Altimmune, or Penn National Gaming?
NEW YORK, Sept. 8, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for NBRV, WIMI, XOS, ALT, and PENN.
Sep 08, 2021 07:01 am ET
Lefamulin Receives Approval in Taiwan for Treatment of Community-Acquired Pneumonia
Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, announced today that its partner, Sumitomo Pharmaceuticals...
Sep 01, 2021 07:01 am ET
Nabriva Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced that it has granted non-statutory stock options...
Aug 31, 2021 04:05 pm ET
Nabriva Therapeutics to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced that Ted Schroeder, Chief Executive Officer at...
Aug 06, 2021 08:30 am ET
Thinking about buying stock in Westport Fuel Systems, Switch, Athersys, Nabriva Therapeutics, or Aurinia Pharmaceuticals?
NEW YORK, Aug. 6, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for WPRT, SWCH, ATHX, NBRV, and AUPH.
Aug 05, 2021 04:01 pm ET
Nabriva Therapeutics Reports Second Quarter 2021 Financial Results and Provides a Corporate Update
Conference call today at 4:30 p.m. Eastern Time- DUBLIN, Ireland, Aug. 05, 2021 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective...
Aug 05, 2021 08:00 am ET
Acurx Pharmaceuticals Joins the Antimicrobials Working Group
WASHINGTON, Aug. 5, 2021 /PRNewswire/ -- The Antimicrobials Working Group (AWG) announced today the addition of Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) (Acurx) to its coalition of companies with the mission to combat drug resistant infections and spur life-saving innovations. This new addition brings AWG's membership to 13 antimicrobial drug companies.
Aug 03, 2021 04:27 pm ET
Nabriva Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced that it has granted non-statutory stock options...
Jul 22, 2021 07:01 am ET
Nabriva Therapeutics to Report Second Quarter 2021 Financial Results and Recent Corporate Highlights on August 5, 2021
Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced that it will report its second quarter financial...
Jul 09, 2021 04:05 pm ET
Nabriva Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced that it has granted non-statutory stock options...
Jun 08, 2021 11:07 am ET
Crestone Joins Antimicrobials Working Group
WASHINGTON, June 8, 2021 /PRNewswire/ -- The Antimicrobials Working Group (AWG) announced today the addition of Crestone, Inc. (Crestone) to its coalition of companies with the mission to combat drug resistant infections and spur life-saving innovations. This new addition brings AWG's membership to 12 antimicrobial drug companies.
Jun 03, 2021 07:01 am ET
Nabriva Agrees to Extension of Principal Debt Repayments Under Existing Loan Agreement with Hercules Capital
Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced that it has reached an agreement with Hercules...
Jun 02, 2021 06:02 pm ET
Nabriva Announces Changes to its Board of Directors
Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, announced today that Dr. Mark Corrigan and Lisa Dalton have...
Jun 01, 2021 07:01 am ET
Nabriva Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced that it has granted non-statutory stock options...
May 25, 2021 05:00 pm ET
Sinovant Sciences and Nabriva Therapeutics Announce Positive Topline Results from Phase 3 Trial of Lefamulin in Chinese Adults with Community Acquired Bacterial Pneumonia (CABP)
Sinovant Sciences, a Chinese biopharmaceutical company dedicated to conducting innovative biomedical R&D in China, and Nabriva Therapeutics (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative...
May 21, 2021 07:01 am ET
Nabriva Therapeutics to Present at the Jefferies Virtual Healthcare Conference
Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced that Ted Schroeder, Chief Executive Offer at...
May 06, 2021 04:01 pm ET
Nabriva Therapeutics Reports First Quarter 2021 Financial Results and Provides Corporate Updates
Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced its financial results for the three months ended...
May 03, 2021 04:05 pm ET
Nabriva Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced that it has granted non-statutory stock options...
Apr 29, 2021 04:05 pm ET
Nabriva Therapeutics to Report First Quarter 2021 Financial Results and Recent Corporate Highlights on May 6, 2021
Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced that it will report its first quarter financial...
Apr 15, 2021 12:12 pm ET
Nabriva Commences Exclusive Distribution of SIVEXTRO® (tedizolid phosphate) in the U.S.
Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced that it has begun exclusive distribution of...
Apr 02, 2021 04:01 pm ET
Nabriva Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced that it has granted non-statutory stock options...
Apr 01, 2021 08:00 am ET
Nabriva Therapeutics to Present at the 20th Annual Needham Virtual Healthcare Conference
Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced that Ted Schroeder, Chief Executive Offer at...
Mar 16, 2021 08:00 am ET
Nabriva Publishes Clinical Data Analysis Highlighting Benefits of Outpatient Management of Community Acquired Bacterial Pneumonia (CABP) with Oral XENLETA® (lefamulin)
Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, announced today that The Journal of Emergency Medicine has...
Mar 11, 2021 04:07 pm ET
Nabriva Therapeutics Reports Fourth Quarter and Year End 2020 Financial Results and Provides Corporate Updates
Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced its financial results for the three months and...
Mar 03, 2021 04:05 pm ET
Nabriva Therapeutics to Report 2020 Financial Results and Recent Corporate Highlights on March 11, 2021
Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced that it will report its fourth quarter and full...
Mar 01, 2021 08:00 am ET
Nabriva Therapeutics Announces $25.4 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules
Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced that it has entered into a definitive agreement...
Feb 26, 2021 08:00 am ET
Nabriva Therapeutics Appoints Daniel Dolan as Chief Financial Officer
Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced the appointment of Daniel Dolan as Chief...
Feb 23, 2021 07:00 am ET
Study Demonstrates Macrolide-Resistance in S. pneumoniae in the United States Exceeds 25 Percent Threshold Set in Current Community-Acquired Bacterial Pneumonia (CABP) Treatment Guidelines
Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, announced the publication of a study documenting the high rates...
Feb 17, 2021 09:04 am ET
UTILITY Therapeutics Joins Antimicrobials Working Group
WASHINGTON, Feb. 17, 2021 /PRNewswire/ -- The Antimicrobials Working Group (AWG) announced today the addition of UTILITY therapeutics Ltd. (UTILITY) to its coalition of companies with the mission to combat drug resistant infections and spur life-saving innovations. This new addition brings AWG's membership to 13 antimicrobial drug companies.
Feb 01, 2021 04:30 pm ET
Nabriva Therapeutics Announces Retirement of its Chief Financial Officer
Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced the retirement of Gary Sender as Chief Financial...
Jan 05, 2021 04:01 pm ET
Nabriva Therapeutics to Participate in Upcoming Virtual Investor Conferences in January
Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced that management will participate in two upcoming...
Dec 10, 2020 11:17 pm ET
Nabriva Therapeutics Announces Pricing of $15 Million Public Offering
Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced the pricing of its public offering of 6,000,000...
Dec 10, 2020 04:01 pm ET
Nabriva Therapeutics Announces Proposed Public Offering
Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced that it has commenced a public offering of its...
Dec 07, 2020 07:00 am ET
Nabriva Therapeutics and Sinovant Sciences Restructure License Agreement for XENLETA for Community-Acquired Bacterial Pneumonia in China
Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, announced the restructuring of its license agreement with...
Dec 03, 2020 08:31 am ET
Thinking about buying stock in Nabriva Therapeutics, Workhorse Group, ReneSola, Riot Blockchain, or Oramed Pharmaceuticals?
NEW YORK, Dec. 3, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for NBRV, WKHS, SOL, RIOT, and ORMP.
Dec 02, 2020 08:00 am ET
Nabriva Therapeutics Announces Date of 1-for-10 Reverse Stock Split
Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced that it will effect a 1-for-10 reverse stock...
Nov 12, 2020 07:01 am ET
Nabriva Therapeutics to Participate in Upcoming Virtual Investor Conferences
Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced that management will participate in two upcoming...
Nov 05, 2020 04:01 pm ET
Nabriva Therapeutics Reports Third Quarter 2020 Financial Results and Provides Corporate Updates
Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced its financial results for the three months ended...
Nov 02, 2020 04:01 pm ET
Nabriva Therapeutics to Report Third Quarter 2020 Financial Results on November 5, 2020
Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced that it will report its third quarter financial...
Oct 13, 2020 07:00 am ET
Nabriva’s XENLETA Demonstrates High Efficacy in Patients of Advanced Age with Community-Acquired Bacterial Pneumonia (CABP)
Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced that in a post-hoc analysis of the Lefamulin...
Sep 10, 2020 08:39 am ET
Nabriva Therapeutics Granted New Technology Add-On Payment for XENLETA® (lefamulin) and CONTEPO™ (fosfomycin) by Centers for Medicare & Medicaid Services
Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, announced today that the Centers for Medicare & Medicaid Services...
Aug 31, 2020 07:00 am ET
Nabriva Therapeutics to Participate in Upcoming Virtual Investor Conferences
Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced that management will participate in two upcoming...
Aug 06, 2020 04:01 pm ET
Nabriva Therapeutics Reports Second Quarter 2020 Financial Results and Provides Corporate Updates
Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced its financial results for the three months ended...
Aug 03, 2020 07:00 am ET
Nabriva Therapeutics to Report Second Quarter 2020 Financial Results on August 6, 2020
Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced that it will report its second quarter financial...
Jul 30, 2020 04:01 pm ET
Nabriva Therapeutics to Present at the 2020 Wedbush PacGrow Healthcare Virtual Conference
Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced that Ted Schroeder, Chief Executive Offer at...
Jul 28, 2020 10:02 am ET
NABRIVA Receives European Approval for XENLETA® (lefamulin) for Treatment of Community-Acquired Pneumonia (CAP)
Nabriva Therapeutics plc (NASDAQ: NBRV) announced today that the European Commission (EC) has issued a legally binding decision for approval of the marketing authorization application for XENLETA™ (lefamulin) for the treatment of community-acquired...
Jul 23, 2020 07:00 am ET
Lefamulin Demonstrates Anti-Inflammatory Activity in Pre-Clinical Study
Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, announced today the results of a pre-clinical study demonstrating...
Jul 22, 2020 07:00 am ET
U.S. Small Cap Stocks Could Outperform The Market During The Recovery And Here Are Four Stocks You Need To Know About
According to Premier Miton Fund Manager Nick Ford in a recent CNBC’s “Squawk Box Europe” interviewi, U.S. small cap stocks are set to outperform the S&P 500 in the uncertain aftermath of the coronavirus crisis. This is big news for small investors...
Jul 16, 2020 04:04 pm ET
XENLETA® (lefamulin) Receives Health Canada Approval for Treatment of Community Acquired Pneumonia
Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, announced today that its partner, Sunovion Pharmaceuticals Canada...
Jul 16, 2020 09:31 am ET
Thinking about buying stock in Plug Power, Nabriva Therapeutics, electroCore Inc, Spirit Airlines, or TOP Ships?
NEW YORK, July 16, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for PLUG, NBRV, ECOR, SAVE, and TOPS.
Jul 15, 2020 04:01 pm ET
Nabriva Therapeutics Enters into Exclusive Agreement to Promote and Distribute SIVEXTRO® (tedizolid phosphate) in the U.S.
Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced that it has entered into an exclusive agreement...
Jun 19, 2020 08:52 pm ET
Nabriva Therapeutics Receives Complete Response Letter from FDA on NDA for CONTEPO™ (fosfomycin) for injection
Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, announced today that it received a Complete Response Letter (CRL)...
May 29, 2020 07:31 pm ET
Nabriva Therapeutics Announces $38 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules
Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced that it has entered into a definitive agreement...
May 29, 2020 08:00 am ET
Nabriva Therapeutics Receives Positive EU CHMP Opinion for XENLETA™ (lefamulin) for the Treatment of Community-Acquired Pneumonia (CAP)
Nabriva Therapeutics plc (NASDAQ: NBRV) announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending approval of XENLETA (lefamulin) for the...
May 27, 2020 04:01 pm ET
Nabriva Therapeutics to Present at the Jefferies Virtual Healthcare Conference
Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced that Ted Schroeder, Chief Executive Offer at...
May 18, 2020 08:00 am ET
National Burden of Macrolide-Resistant Streptococcus Pneumoniae in the United States From Blood and Respiratory Tract Cultures Approaches 40 Percent
Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, announced the publication of a study entitled, A Multicenter...
May 11, 2020 04:01 pm ET
Nabriva Therapeutics Reports First Quarter 2020 Financial Results and Provides Corporate Updates
Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced its financial results for the three months ended...
May 11, 2020 07:00 am ET
Nabriva Therapeutics to Present at the BofA Securities 2020 Virtual Health Care Conference
Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced that Ted Schroeder, Chief Executive Offer at...
May 08, 2020 07:00 am ET
Nabriva Therapeutics to Report First Quarter 2020 Financial Results on May 11, 2020
Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced that it will report its first quarter financial...
May 05, 2020 07:00 am ET
XENLETA® (Lefamulin) Treatment Results in a Rapid Time-to-Clinical Response in Hospitalized Patients with Community-Acquired Bacterial Pneumonia (CABP)
Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, announced today that Open Forum Infectious Diseases, an official...
Apr 09, 2020 07:00 am ET
Centers for Medicare & Medicaid Services Issues Product-Specific J-Code for XENLETA
Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced that the Centers for Medicare and Medicaid...
Apr 08, 2020 07:00 am ET
Nabriva Therapeutics to Present at the 19th Annual Needham Virtual Healthcare Conference
Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced that Ted Schroeder, Chief Executive Offer at...
Mar 12, 2020 04:01 pm ET
Nabriva Therapeutics Reports Fourth Quarter and Year End 2019 Financial Results and Recent Corporate Highlights
Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced its financial results for the three months and...
Mar 10, 2020 04:01 pm ET
Nabriva Therapeutics to Report 2019 Financial Results and Recent Corporate Highlights on March 12, 2020
Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced that it will report its fourth quarter and full...
Mar 02, 2020 04:01 pm ET
Nabriva Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced that it has granted non-statutory stock options...
Feb 05, 2020 04:01 pm ET
Nabriva Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced that it has granted non-statutory stock options...
Jan 08, 2020 04:01 pm ET
Nabriva Therapeutics Receives FDA Acknowledgement of New Drug Application Resubmission for Intravenous CONTEPO™ (fosfomycin) for Injection
Nabriva Therapeutics plc (NASDAQ: NBRV), a commercial-stage biopharmaceutical company engaged in the development of innovative anti-infective agents to treat serious infections, announced that the U.S. Food and Drug Administration (FDA) has...
Dec 20, 2019 08:37 am ET
Nabriva Therapeutics Announces $20 Million Registered Direct Offering
Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced that it has entered into a definitive agreement...
Dec 20, 2019 06:00 am ET
Nabriva Therapeutics Resubmits New Drug Application for Intravenous CONTEPO™ (fosfomycin) for Injection
Nabriva Therapeutics plc (NASDAQ: NBRV), a commercial-stage biopharmaceutical company engaged in the development of innovative anti-infective agents to treat serious infections, announced today that it has resubmitted its New Drug Application (NDA)...
Dec 02, 2019 04:01 pm ET
Nabriva Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced that it has granted non-statutory stock options...
Nov 21, 2019 04:01 pm ET
Nabriva Therapeutics to Present at the 31st Annual Piper Jaffray Healthcare Conference
Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced that Gary Sender Chief Financial Officer and...
Nov 18, 2019 07:00 am ET
Nabriva Therapeutics Commends the CDC on the 2019 Antibiotic Resistance Threats Report, Highlighting the Need for New Antibiotics Aligned with Antibiotic Stewardship
Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, emphasized the significance of the new updated report from the...
Nov 12, 2019 04:01 pm ET
Nabriva Therapeutics Reports Third Quarter 2019 Financial Results and Recent Corporate Highlights
Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced its financial results for the three and nine...
Nov 01, 2019 04:01 pm ET
Nabriva Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced that it has granted non-statutory stock options...
Oct 31, 2019 07:00 am ET
Nabriva Therapeutics to Report Third-Quarter 2019 Financial Results on November 12, 2019
Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced that it will report its third-quarter 2019...
Oct 15, 2019 07:00 am ET
Nabriva to Present Data at the CHEST Annual Meeting Demonstrating the Safety and Efficacy of Newly FDA-Approved XENLETA (lefamulin) for the Treatment of Community-Acquired Bacterial Pneumonia (CABP)
Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, announced today that it will present data on the pooled results...
Oct 01, 2019 04:01 pm ET
Nabriva Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced that it has granted non-statutory stock options...
Oct 01, 2019 10:07 am ET
Antimicrobials Working Group Highlights Member Company Participation at IDWeek 2019
WASHINGTON, Oct. 1, 2019 /PRNewswire/ -- The Antimicrobials Working Group (AWG), a coalition of companies with the mission to combat drug-resistant infections and spur life-saving innovations, today announced that eleven of its member companies will present data from their clinical and research programs at IDWeek 2019 to be held October 2-6, 2019 in Washington D.C.
Sep 27, 2019 12:15 pm ET
Lefamulin Evaluation Against Pneumonia 2 (LEAP 2) Study Results Published in the Journal of the American Medical Association
Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, announced today that the Journal of the American Medical...
Sep 26, 2019 04:01 pm ET
Nabriva to Present Data from XENLETA (lefamulin) and CONTEPO (fosfomycin) Development Programs at IDWeek 2019
Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, announced today that data from its XENLETA™ (lefamulin) and...
Sep 18, 2019 07:00 am ET
Nabriva Therapeutics to Present at the 2019 Cantor Global Healthcare Conference
Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced that Chief Executive Officer Ted Schroeder will...
Sep 09, 2019 07:00 am ET
Nabriva’s XENLETA™ (lefamulin) for the Treatment of Community-Acquired Bacterial Pneumonia (CABP) Now Available in the U.S.
Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, announced today that the oral and intravenous (IV) formulations...
Sep 06, 2019 04:01 pm ET
Nabriva Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced that it has granted non-statutory stock options...
Sep 06, 2019 07:00 am ET
Nabriva Therapeutics Earns $5 Million Milestone Payment under its License Agreement with Sinovant Sciences
Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced that Nabriva has earned a $5 million milestone...
Sep 05, 2019 07:00 am ET
Nabriva Therapeutics to Present Data at ASM/ESCMID Conference Demonstrating Utility of Xenleta™ (lefamulin) for Patients with Community-Acquired Bacterial Pneumonia (CABP)
Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced that it will present data at the ASM/ESCMID...
Aug 28, 2019 07:00 am ET
Nabriva Therapeutics to Present at the 17th Annual Morgan Stanley Global Healthcare Conference
Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced that Chief Executive Officer Ted Schroeder will...
Aug 19, 2019 03:41 pm ET
Nabriva Therapeutics Receives U.S. FDA Approval of Xenleta™ (lefamulin) to Treat Community-Acquired Bacteria Pneumonia (CABP)
Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, announced today that the U.S. Food and Drug Administration (FDA)...
Aug 16, 2019 07:00 am ET
Nabriva Therapeutics Provides Update on the Planned Resubmission of the New Drug Application for Intravenous CONTEPO™ (fosfomycin) for Injection
Nabriva Therapeutics plc (NASDAQ: NBRV), a clinical-stage biopharmaceutical company engaged in the development of innovative anti-infective agents to treat serious infections, announced today that following its receipt of final Type A Meeting...
Aug 08, 2019 07:00 am ET
Nabriva Therapeutics Reports Second Quarter 2019 Financial Results and Recent Corporate Highlights
Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the development of innovative anti-infective agents to treat serious infections, today announced its financial results for the three and six months ended June 30, 2019...
Aug 06, 2019 07:00 am ET
Nabriva Therapeutics to Present at the 2019 Wedbush PacGrow Healthcare Conference
Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the development of innovative anti-infective agents to treat serious infections, today announced that Chief Commercial Officer Francesco Maria Lavino will provide a...
Jul 08, 2019 11:37 am ET
FINAL DEADLINE: ROSEN, A GLOBALLY RECOGNIZED LAW FIRM, Reminds Nabriva Therapeutics plc Investors of Important Deadline Today in the Securities Class Action – NBRV
Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Nabriva Therapeutics plc (NASDAQ: NBRV) from November 1, 2018 through April 30, 2019, inclusive (the “Class Period”) of the July 8, 2019 lead plaintiff...
Jul 08, 2019 10:00 am ET
MONDAY DEADLINE REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Nabriva Therapeutics plc and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Nabriva Therapeutics plc (“Nabriva” or “the Company”) (NASDAQ:
Jul 05, 2019 03:00 pm ET
DEADLINE ALERT - (NBRV) Nabriva Therapeutics PLC Bronstein, Gewirtz & Grossman, LLC Reminds Investors with Losses Exceeding $50K of Class Action and Lead Plaintiff Deadline: July 8, 2019
Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Nabriva Therapeutics PLC (“Nabriva” or the “Company”) (NASDAQ: NBRV) and certain of its officers, on behalf of...
Jul 05, 2019 10:47 am ET
MONDAY DEADLINE ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Nabriva Therapeutics plc and Encourages Investors with Losses in Excess of $100,000 to Contact the Fir
The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Nabriva Therapeutics plc (“Nabriva” or “the Company”) (NASDAQ: NBRV) for violations of §§10(b) and 20(a) of the Securities...
Jul 05, 2019 10:00 am ET
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Nabriva Therapeutics plc of Class Action Lawsuit and Upcoming Deadline – NBRV
Pomerantz LLP announces that a class action lawsuit has been filed against Nabriva Therapeutics plc (“Nabriva” or the “Company”) (NASDAQ: NBRV) and certain of its officers.  The class action, filed in United States District Court, for the Southern...
Jul 03, 2019 08:30 am ET
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Nabriva Therapeutics, Equity Bancshares, Revlon and AAC Holdings and Encourages Investors to Contact th
Bragar Eagel & Squire, P.C. reminds investors that class action lawsuits have been commenced on behalf of stockholders Nabriva Therapeutics Plc, Equity Bancshares, Inc., Revlon, Inc., and AAC Holdings, Inc. Stockholders have until the deadlines...
Jul 02, 2019 11:01 am ET
NBRV: Zhang Investor Law Reminds Investors of July 8 Deadline in Securities Class Action Lawsuit Nabriva Therapeutics plc – NBRV
Zhang Investor Law announces the filing of a class action lawsuit on behalf of shareholders who bought shares of Nabriva Therapeutics plc (NASDAQ: NBRV) from November 1, 2018 through April 30, 2019, inclusive (the “Class Period”). The lawsuit seeks...
Jul 01, 2019 10:06 am ET
7-DAY DEADLINE ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Nabriva Therapeutics plc and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Nabriva Therapeutics plc (“Nabriva” or “the Company”) (NASDAQ: NBRV) for violations of §§10(b) and 20(a) of the Securities...
Jul 01, 2019 09:13 am ET
X-Biotix Therapeutics Joins Antimicrobials Working Group
WASHINGTON, July 1, 2019 /PRNewswire/ -- The Antimicrobials Working Group (AWG) announced today the addition of X-Biotix Therapeutics, Inc. (X-Biotix) to its coalition of companies with the mission to combat drug resistant infections and spur life-saving innovations. This new addition brings AWG's membership to 14 antimicrobial drug companies.
Jun 30, 2019 04:00 pm ET
ROSEN, A TOP RANKED LAW FIRM, Reminds Nabriva Therapeutics plc Investors of Important July 8th Deadline in the Securities Class Action – NBRV
Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Nabriva Therapeutics plc (NASDAQ: NBRV) from November 1, 2018 through April 30, 2019, inclusive (the “Class Period”) of the July 8, 2019 lead plaintiff...
Jun 28, 2019 05:33 pm ET
Deadline Reminder: The Law Offices of Howard G. Smith Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Nabriva Therapeutics plc
Law Offices of Howard G. Smith reminds investors of the upcoming July 8, 2019 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased Nabriva Therapeutics plc  (“Nabriva” or the “Company”)...
Jun 28, 2019 03:00 pm ET
KSHB, NBRV & EQBK- Class Action Upcoming Deadline - Bronstein, Gewirtz & Grossman, LLC
Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against the following publicly-traded companies. You can review a copy of the Complaints by visiting the links below or you may...
Jun 27, 2019 09:30 pm ET
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against KushCo Holdings, Nabriva Therapeutics, Equity Bancshares, and Revlon and Encourages Investors to Contac
Bragar Eagel & Squire, P.C. reminds investors that class action lawsuits have been commenced on behalf of stockholders of KushCo Holdings, Inc., Nabriva Therapeutics, plc, Equity Bancshares, Inc., and Revlon, Inc. Stockholders have until the...
Jun 27, 2019 12:32 pm ET
UPCOMING DEADLINE REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Nabriva Therapeutics plc and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Nabriva Therapeutics plc (“Nabriva” or “the Company”) (NASDAQ:
Jun 26, 2019 03:57 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Nabriva Therapeutics plc of Class Action Lawsuit and Upcoming Deadline – NBRV
Pomerantz LLP announces that a class action lawsuit has been filed against Nabriva Therapeutics plc (“Nabriva” or the “Company”) (NASDAQ: NBRV) and certain of its officers.  The class action, filed in United States District Court, for the Southern...
Jun 26, 2019 12:02 pm ET
Zhang Investor Law Reminds Investors of July 8 Deadline in Securities Class Action Lawsuit Nabriva Therapeutics plc – NBRV
Zhang Investor Law announces the filing of a class action lawsuit on behalf of shareholders who bought shares of Nabriva Therapeutics plc (NASDAQ: NBRV) from November 1, 2018 through April 30, 2019, inclusive (the “Class Period”). The lawsuit seeks...
Jun 25, 2019 01:03 pm ET
Glancy Prongay & Murray Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Nabriva Therapeutics plc
Glancy Prongay & Murray LLP (“GPM”) reminds investors of the upcoming July 8, 2019 deadline to file a lead plaintiff motion in the class action filed on behalf of Nabriva Therapeutics plc  (“Nabriva” or the “Company”) (NASDAQ: NBRV) investors who...
Jun 24, 2019 04:01 pm ET
Nabriva Therapeutics Announces European Medicines Agency (EMA) Validation of Marketing Authorization Application for Lefamulin
Nabriva Therapeutics plc (NASDAQ: NBRV), a clinical-stage biopharmaceutical company engaged in the development of innovative anti-infective agents to treat serious infections, today announced that the European Medicines Agency (EMA) has determined...
Jun 24, 2019 11:46 am ET
UPCOMING DEADLINE ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Nabriva Therapeutics plc and Encourages Investors with Losses in Excess of $100,000 to Contact the F
The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Nabriva Therapeutics plc (“Nabriva” or “the Company”) (NASDAQ: NBRV) for violations of §§10(b) and 20(a) of the Securities...
Jun 22, 2019 02:00 pm ET
TOP RANKED ROSEN LAW FIRM Reminds Nabriva Therapeutics plc Investors of Important July 8th Deadline in the Securities Class Action – NBRV
Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Nabriva Therapeutics plc (NASDAQ: NBRV) from November 1, 2018 through April 30, 2019, inclusive (the “Class Period”) of the July 8, 2019 lead plaintiff...
Jun 21, 2019 09:30 pm ET
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Nabriva Therapeutics, Equity Bancshares, Revlon, and AAC Holdings and Encourages Investors to Contact t
Bragar Eagel & Squire, P.C. reminds investors that class action lawsuits have been commenced on behalf of stockholders of Nabriva Therapeutics, PLC, Equity Bancshares, Inc., Revlon, Inc., and AAC Holdings Inc.  Stockholders have until the deadlines...
Jun 21, 2019 03:02 pm ET
NBRV DEADLINE: Pawar Law Group Reminds Investors of Deadline in Securities Class Action Lawsuit Against Nabriva Therapeutics plc – NBRV
Pawar Law Group announces that a class action lawsuit has been filed on behalf of shareholders who purchased shares of Nabriva Therapeutics plc (NASDAQ: NBRV) from November 1, 2018 through April 30, 2019, inclusive (the “Class Period”). The lawsuit...
Jun 21, 2019 03:00 pm ET
KSHB, NBRV & EQBK-  Class Action - Bronstein, Gewirtz & Grossman, LLC
Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against the following publicly-traded companies. You can review a copy of the Complaints by visiting the links below or you may...
Jun 21, 2019 01:48 pm ET
Deadline Reminder: The Law Offices of Howard G. Smith Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Nabriva Therapeutics plc
Law Offices of Howard G. Smith reminds investors of the upcoming July 8, 2019 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased Nabriva Therapeutics plc  (“Nabriva” or the “Company”)...
Jun 21, 2019 07:00 am ET
Nabriva Therapeutics to Present Data at ASM Microbe Demonstrating Potential of Lefamulin for Patients with Community-acquired Bacterial Pneumonia (CABP) and CONTEPO™ (fosfomycin) for injection to Trea
Nabriva Therapeutics plc (NASDAQ: NBRV), a clinical-stage biopharmaceutical company engaged in the development of innovative anti-infective agents to treat serious infections, today announced that it will present data at ASM Microbe 2019 to be...
Jun 20, 2019 04:28 pm ET
Glancy Prongay & Murray Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Nabriva Therapeutics plc
Glancy Prongay & Murray LLP (“GPM”) reminds investors of the upcoming July 8, 2019 deadline to file a lead plaintiff motion in the class action filed on behalf of Nabriva Therapeutics plc  (“Nabriva” or the “Company”) (NASDAQ: NBRV) investors who...
Jun 20, 2019 12:47 pm ET
SHAREHOLDER ALERT:  Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Nabriva Therapeutics plc of Class Action Lawsuit and Upcoming Deadline – NBRV
Pomerantz LLP announces that a class action lawsuit has been filed against Nabriva Therapeutics plc (“Nabriva” or the “Company”) (NASDAQ:  NBRV) and certain of its officers.   The class action, filed in United States District Court, for the...
Jun 19, 2019 07:00 am ET
Nabriva Therapeutics Submits Type A Meeting Request to FDA for Intravenous CONTEPO™ (fosfomycin) for injection
Nabriva Therapeutics plc (NASDAQ: NBRV), a clinical-stage biopharmaceutical company engaged in the development of innovative anti-infective agents to treat serious infections, announced today that it has submitted a Type A Meeting Request and...
Jun 18, 2019 09:47 am ET
Zhang Investor Law Reminds Investors of Deadline in Securities Class Action Lawsuit Nabriva Therapeutics plc – NBRV
Zhang Investor Law announces the filing of a class action lawsuit on behalf of shareholders who bought shares of Nabriva Therapeutics plc (NASDAQ: NBRV) from November 1, 2018 through April 30, 2019, inclusive (the “Class Period”). The lawsuit seeks...
Jun 17, 2019 07:51 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Nabriva Therapeutics plc of Class Action Lawsuit and Upcoming Deadline - NBRV
NEW YORK, June 17, 2019 /CNW/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Nabriva Therapeutics plc ("Nabriva" or the "Company") (NASDAQ:  NBRV) and certain of its officers. The class action, filed in United States District Court, for the Southern District of New York, and indexed under 19-cv-04713, is on behalf of a class consisting of all persons and entities who purchased or otherwise acquired Nabriva securities between November 1, 2018 and April 30, 2019, inclusive (the "Class Period"). Plaintiff pursues claims against the Defendants under the Securities
Jun 17, 2019 09:57 am ET
INVESTOR ACTION NOTICE: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Nabriva Therapeutics plc and Encourages Investors with Losses in Excess of $100,000 to Contact the Fi
The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Nabriva Therapeutics plc (“Nabriva” or “the Company”) (NASDAQ: NBRV) for violations of §§10(b) and 20(a) of the Securities...
Jun 14, 2019 10:00 pm ET
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Indivior, Boston Scientific, KushCo, and Nabriva and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C. reminds investors that class action lawsuits have been commenced on behalf of stockholders of Indivior PLC, Boston Scientific Corporation, KushCo Holdings, Inc., and Nabriva Therapeutics plc.  Stockholders have until the...
Jun 14, 2019 03:00 pm ET
KSHB, NBRV & EQBK - Bronstein, Gewirtz & Grossman, LLC Class Action Update
Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against the following publicly-traded companies. You can review a copy of the Complaints by visiting the links below or you may...
Jun 12, 2019 05:41 pm ET
SHAREHOLDER ALERT:  Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Nabriva Therapeutics plc of Class Action Lawsuit and Upcoming Deadline – NBRV
Pomerantz LLP announces that a class action lawsuit has been filed against Nabriva Therapeutics plc (“Nabriva” or the “Company”) (NASDAQ: NBRV) and certain of its officers.  The class action, filed in United States District Court, for the Southern...
Jun 10, 2019 02:25 pm ET
INVESTOR ACTION REMINDER: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Nabriva Therapeutics plc and Encourages Investors with Losses in Excess of $100,000 to Contact the
The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Nabriva Therapeutics plc (“Nabriva” or “the Company”) (NASDAQ: NBRV) for violations of §§10(b) and 20(a) of the Securities...
Jun 07, 2019 10:00 am ET
KushCo Holdings, Inc. (KSHB), Nabriva Therapeutics PLC (NBRV), Equity Bancshares, Inc. (EQBK) -  Bronstein, Gewirtz & Grossman, LLC Class Action Reminder
Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against the following publicly-traded companies. You can review a copy of the Complaints by visiting the links below or you may...
Jun 05, 2019 10:00 pm ET
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Indivior, Boston Scientific, KushCo, and Nabriva and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C. reminds investors that class action lawsuits have been commenced on behalf of stockholders of Indivior PLC, Boston Scientific Corporation, KushCo Holdings, Inc., and Nabriva Therapeutics plc.  Stockholders have until the...
Jun 05, 2019 06:55 pm ET
ROSEN, A TOP RANKED LAW FIRM, Reminds Nabriva Therapeutics plc Investors of Important Deadline in the Securities Class Action; Encourages Investors with Losses in Excess of $100K to Contact the Firm –
Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Nabriva Therapeutics plc (NASDAQ: NBRV) from November 1, 2018 through April 30, 2019, inclusive (the “Class Period”) of the July 8, 2019 lead plaintiff...
Jun 05, 2019 06:52 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Nabriva Therapeutics plc of Class Action Lawsuit and Upcoming Deadline – NBRV
Pomerantz LLP announces that a class action lawsuit has been filed against Nabriva Therapeutics plc (“Nabriva” or the “Company”) (NASDAQ:  NBRV) and certain of its officers.  The class action, filed in United States District Court, for the Southern...
Jun 04, 2019 04:01 pm ET
Nabriva Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the development of innovative anti-infective agents to treat serious infections, today announced that it has granted non-statutory stock options to purchase an...
Jun 04, 2019 11:20 am ET
INVESTOR ACTION ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Nabriva Therapeutics plc and Encourages Investors with Losses in Excess of $100,000 to Contact the Fir
The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Nabriva Therapeutics plc (“Nabriva” or “the Company”) (NASDAQ: NBRV) for violations of §§10(b) and 20(a) of the Securities...
Jun 03, 2019 03:19 pm ET
Pawar Law Group Reminds Investors of Deadline in Securities Class Action Lawsuit Against Nabriva Therapeutics plc – NBRV
Pawar Law Group announces that a class action lawsuit has been filed on behalf of shareholders who purchased shares of Nabriva Therapeutics plc (NASDAQ: NBRV) from November 1, 2018 through April 30, 2019, inclusive (the “Class Period”). The lawsuit...
May 31, 2019 03:00 pm ET
KushCo Holdings, Inc. (KSHB), Nabriva Therapeutics PLC (NBRV), Equity Bancshares, Inc. (EQBK) -  Bronstein, Gewirtz & Grossman, LLC Class Action
Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against the following publicly-traded companies. You can review a copy of the Complaints by visiting the links below or you may...
May 30, 2019 05:00 am ET
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Indivior, Boston Scientific, KushCo, and Nabriva and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C. reminds investors that class action lawsuits have been commenced on behalf of stockholders of Indivior PLC, Boston Scientific Corporation, Inc., KushCo Holdings, Inc., and Nabriva Therapeutics plc.  Stockholders have...
May 28, 2019 05:44 pm ET
Robbins Arroyo LLP: Nabriva Therapeutics plc (NBRV) Misled Shareholders According to a Recently Filed Lawsuit
Shareholder rights law firm Robbins Arroyo LLP reminds investors that a purchaser of Nabriva Therapeutics plc filed a class action complaint against Nabriva Therapeutics plc (NASDAQ: NBRV) for alleged violations of the Securities Exchange Act of 1934 between November 1, 2018 and April 30, 2019.
May 28, 2019 05:15 pm ET
LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In Nabriva Therapeutics plc To Contact The Firm
Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Nabriva Therapeutics plc (“Nabriva” or the “Company”) (NASDAQ:NBRV) of the July 8, 2019 deadline to seek the role of lead plaintiff in a federal securities class...
May 27, 2019 01:50 pm ET
INVESTOR ACTION NOTICE: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Nabriva Therapeutics plc and Encourages Investors with Losses in Excess of $100,000 to Contact the Fi
The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Nabriva Therapeutics plc (“Nabriva” or “the Company”) (NASDAQ: NBRV) for violations of §§10(b) and 20(a) of the Securities...
May 24, 2019 03:00 pm ET
KushCo Holdings, Inc. (KSHB), Nabriva Therapeutics PLC (NBRV), Equity Bancshares, Inc. (EQBK) -  Bronstein, Gewirtz & Grossman, LLC Class Action
Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against the following publicly-traded companies. You can review a copy of the Complaints by visiting the links below or you may...
May 23, 2019 11:45 am ET
NABRIVA LAWSUIT FILED: Rosen Law Firm Announces Filing of Securities Class Action Lawsuit Against Nabriva Therapeutics plc; Encourages Investors with Losses in Excess of $100K to Contact the Firm – NB
Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of Nabriva Therapeutics plc (NASDAQ: NBRV) from November 1, 2018 through April 30, 2019, inclusive (the...
May 23, 2019 05:00 am ET
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Indivior, Boston Scientific, KushCo, and Nabriva and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C. reminds investors that class action lawsuits have been commenced on behalf of stockholders of Indivior PLC, Boston Scientific Corporation, Inc., KushCo Holdings, Inc., and Nabriva Therapeutics plc.  Stockholders have...
May 22, 2019 03:54 pm ET
NBRV DEADLINE: Pawar Law Group Reminds Investors of Deadline in Securities Class Action Lawsuit Against Nabriva Therapeutics plc – NBRV
Pawar Law Group announces that a class action lawsuit has been filed on behalf of shareholders who purchased shares of Nabriva Therapeutics plc (NASDAQ: NBRV) from November 1, 2018 through April 30, 2019, inclusive (the “Class Period”). The lawsuit...
May 22, 2019 03:14 pm ET
Pomerantz Law Firm Announces the Filing of a Class Action against Nabriva Therapeutics plc and Certain Officers – NBRV
Pomerantz LLP announces that a class action lawsuit has been filed against Nabriva Therapeutics plc (“Nabriva” or the “Company”) (NASDAQ: NBRV) and certain of its officers.  The class action, filed in United States District Court, for the Southern...
May 22, 2019 07:00 am ET
Nabriva Therapeutics to Present at the Jefferies 2019 Healthcare Conference
Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the development of innovative anti-infective agents to treat serious infections, today announced that Ted Schroeder, Chief Executive Officer, will provide a company...
May 21, 2019 06:02 pm ET
Deadline Reminder: The Law Offices of Howard G. Smith Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Nabriva Therapeutics plc
Law Offices of Howard G. Smith reminds investors of the upcoming July 8, 2019 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased Nabriva Therapeutics plc (“Nabriva” or the “Company”) (NASDAQ: NBRV) securities between November 1, 2018 and April 30, 2019, inc
May 21, 2019 04:27 pm ET
LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In Nabriva Therapeutics plc To Contact The Firm
Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Nabriva Therapeutics plc (“Nabriva” or the “Company”) (NASDAQ:NBRV) of the July 8, 2019 deadline to seek the role of lead plaintiff in a federal securities class...
May 20, 2019 02:50 pm ET
INVESTOR ACTION REMINDER: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Nabriva Therapeutics plc and Encourages Investors with Losses in Excess of $100,000 to Contact the
The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Nabriva Therapeutics plc (“Nabriva” or “the Company”) (NASDAQ: NBRV) for violations of §§10(b) and 20(a) of the Securities...
May 17, 2019 10:27 am ET
NBRV ALERT: Zhang Investor Law Reminds Investors of Deadline in Securities Class Action Lawsuit Against Nabriva Therapeutics plc – NBRV
Zhang Investor Law announces the filing of a class action lawsuit on behalf of shareholders who bought shares of Nabriva Therapeutics plc (NASDAQ: NBRV) from November 1, 2018 through April 30, 2019, inclusive (the “Class Period”). The lawsuit seeks...
May 17, 2019 05:00 am ET
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Indivior, Boston Scientific, KushCo, and Nabriva and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C. reminds investors that class action lawsuits have been commenced on behalf of stockholders of Indivior PLC, Boston Scientific Corporation, Inc., KushCo Holdings, Inc., and Nabriva Therapeutics plc.  Stockholders have...
May 16, 2019 07:39 pm ET
Glancy Prongay & Murray Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Nabriva Therapeutics plc
Glancy Prongay & Murray LLP (“GPM”) reminds investors of the upcoming July 8, 2019 deadline to file a lead plaintiff motion in the class action filed on behalf of Nabriva Therapeutics plc (“Nabriva” or the “Company”) (NASDAQ: 
May 14, 2019 05:30 pm ET
NABRIVA DEADLINE ALERT: Rosen Law Firm Reminds Nabriva Therapeutics plc Investors of Important Deadline in the Securities Class Action– NBRV
Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Nabriva Therapeutics plc (NASDAQ:NBRV) from November 1, 2018 through April 30, 2019, inclusive (the “Class Period”) of the July 8, 2019 lead plaintiff deadline in the securities class action. The lawsuit seeks to recover damages for Nabriva investors under the federal securities laws.
May 14, 2019 05:01 pm ET
NABRIVA THERAPEUTICS PLC ALERT: Wolf Haldenstein Adler Freeman & Herz LLP announces that a securities class action lawsuit has been filed in the United States District Court for the Southern
Wolf Haldenstein Adler Freeman & Herz LLP   announces that  a federal securities class action lawsuit has been filed in the United States District Court for the Southern District of New York on behalf of persons and entities that purchased or...
May 14, 2019 04:09 pm ET
INVESTOR ALERT: Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of Nabriva Therapeutics plc Investors (NBRV)
Law Offices of Howard G. Smith announces that a class action lawsuit has been filed on behalf of investors who purchased Nabriva Therapeutics plc (“Nabriva” or the “Company”) (NASDAQ: NBRV) securities between November 1, 2018 and April 30, 2019, inclusive (the “Class Period”). Nabriva investors have until July 8,
May 14, 2019 11:20 am ET
INVESTOR ACTION ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Nabriva Therapeutics plc and Encourages Investors with Losses in Excess of $100,000 to Contact the Fir
The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Nabriva Therapeutics plc (“Nabriva” or “the Company”) (NASDAQ: NBRV) for violations of §§10(b) and 20(a) of the Securities...
May 13, 2019 04:17 pm ET
IMPORTANT INVESTOR REMINDER: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Nabriva Therapeutics plc and Encourages Investors with Losses in Excess of $100,000 to Contact t
The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Nabriva Therapeutics plc (“Nabriva” or “the Company”) (NASDAQ:
May 13, 2019 12:25 pm ET
LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In Nabriva Therapeutics plc To Contact The Firm
Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Nabriva Therapeutics plc (“Nabriva” or the “Company”) (NASDAQ:NBRV) of the July 8, 2019 deadline to seek the role of lead plaintiff in a federal securities class...
May 10, 2019 03:00 pm ET
SHAREHOLDER ALERT - Nabriva Therapeutics PLC (NBRV) Bronstein, Gewirtz & Grossman, LLC Announces Class Action and Lead Plaintiff Deadline: July 8, 2019
Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Nabriva Therapeutics PLC (“Nabriva” or the “Company”) (NASDAQ: NBRV) and certain of its officers, on behalf of...
May 10, 2019 12:01 pm ET
IMPORTANT INVESTOR ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Nabriva Therapeutics plc and Encourages Investors with Losses in Excess of $100,000 to Contact the
The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Nabriva Therapeutics plc (“Nabriva” or “the Company”) (NASDAQ:
May 10, 2019 08:00 am ET
Glancy Prongay & Murray LLP Files a Securities Class Action Behalf of Nabriva Therapeutics plc Investors (NBRV)
Glancy Prongay & Murray LLP (“GPM”) announces that it has filed a class action lawsuit in the United States District Court for the Southern District of New York, captioned Enriquez v. Nabriva Therapeutics plc et al., (Case No. 1:19cv04183), on...
May 10, 2019 07:00 am ET
Nabriva Therapeutics Reports First Quarter 2019 Financial Results and Recent Corporate Highlights
Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the development of innovative anti-infective agents to treat serious infections, today announced its financial results for the three months ended March 31, 2019 and...
May 09, 2019 09:00 pm ET
Bragar Eagel & Squire, P.C. Announces That a Class Action Lawsuit Has Been Filed Against Nabriva Therapeutics plc (NASDAQ: NBRV) and Encourages Nabriva Investors to Contact the Firm
Bragar Eagel & Squire, P.C. announces that a class action lawsuit has been filed in the U.S. District Court for the Southern District of New York on behalf of all persons or entities who purchased or otherwise acquired Nabriva Therapeutics plc...
May 09, 2019 05:24 pm ET
EQUITY ALERT: Rosen Law Firm Announces Filing of Securities Class Action Lawsuit Against Nabriva Therapeutics plc – NBRV
Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of Nabriva Therapeutics plc (NASDAQ:NBRV) from November 1, 2018 through April 30, 2019, inclusive (the “Class Period”). The lawsuit seeks to recover damages for Nabriva investors under the federal securities laws.

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.